★ 宏观动态 ★ 预制菜国家标准征求意见：中央厨房制作的菜肴等或不属于预制菜 2月6日，国家卫生健康委发布了《食品安全国家标准 预制菜》（征求意见稿），面向社会公开征求意见。标 准明确：①预制菜是以一种或多种食用农产品及其制品为原料，使用或不使用调味料等辅料，不添加防腐剂， 经工业化预加工(如搅拌，腌制，滚揉，成型，炒，炸，烤，煮，蒸等)制成，配以或不配以调味料包，加热或 熟制后方可食用的预包装菜肴产品。②预制菜不包括主食类食品、净菜类食品、即食食品和中央厨房制作的菜 肴。③尽量缩短预制菜的产品保质期，最长不应超过12个月。③不得使用防腐剂，尽可能减少食品添加剂的使 用。 大商所2026年春节期间交易时间安排：2月15日至2月23日休市，24日起照常开市 大连商品交易所2026年春节期间交易时间安排通知如下：2月15日（周日）至2月23日（周一）休市，2月24日 （周二）起照常开市。2月14日（周六）、2月28日（周六）为周末休市。2月13日（周五）晚上不进行夜盘交 易。2月24日（周二）所有合约集合竞价时间为上午08:55-09:00。2月24日（周二）当晚恢复夜盘交易。 上海黄金交易所：调整部分合约保证金 ...

Group 1 - The core point of the article is that Aihua Long received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws, leading to a formal case being opened against the company [1] Group 2 - The notice was issued on February 6, 2026, indicating the timeline of the regulatory action taken against the company [1]

格隆汇2月6日丨亚辉龙(688575.SH)公布，公司于2026年2月6日收到中国证券监督管理委员会(以下简 称"中国证监会")下发的《立案告知书》(编号：证监立案字00720262号)，因涉嫌信息披露违法违规，根 据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司予以 立案。目前公司各项经营活动和业务均正常开展。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

特此公告。 深圳市亚辉龙生物科技股份有限公司 董事会 2026 年 2 月 7 日 深圳市亚辉龙生物科技股份有限公司 关于收到中国证券监督管理委员会立案告知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）于 2026 年 2 月 6 日收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立案告 知书》（编号：证监立案字 00720262 号），因涉嫌信息披露违法违规，根据《中 华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会 决定对公司予以立案。 目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合 中国证监会的相关工作，并严格按照相关法律法规和监管要求及时履行信息披露 义务。公司所有信息均以上海证券交易所官网（www.sse.com.cn）及相关指定信 息披露媒体刊登的公告为准。敬请广大投资者关注公司后续公告，并注意投资风 险。 证券代码：688575 证券简称：亚辉龙 公告编号：2026-007 ...

智通财经APP讯，亚辉龙(688575.SH)公告，公司于2026年2月6日收到中国证券监督管理委员会下发的 《立案告知书》，因涉嫌信息披露违法违规，根据相关法律法规，中国证监会决定对公司予以立案。 ...

亚辉龙公告，公司于2026年2月6日收到中国证监会下发的《立案告知书》，因涉嫌信息披露违法违规， 根据法律法规，中国证监会决定对公司予以立案。 ...

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. (referred to as Yahui Long) has disclosed a strategic cooperation framework agreement, which is suspected of misleading statements. The regulatory authority has initiated an investigation into Yahui Long to ensure the healthy development of the market [2] Group 1 - Yahui Long signed a strategic cooperation framework agreement on January 7, 2026 [2] - The announcement regarding the agreement has raised concerns about potential misleading statements [2] - The regulatory authority has launched an investigation into Yahui Long to address these concerns [2]

近日，我会已对亚辉龙立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 据证监会2月6日消息，2026年1月7日，深圳市亚辉龙生物科技股份有限公司(简称亚辉龙)披露签署战略 合作框架协议的公告，涉嫌误导性陈述。 ...

证监会对亚辉龙公告涉嫌误导性陈述立案调查。 ...

Core Viewpoint - The company, YHLO Biotech, is facing a significant decline in profits after experiencing explosive growth during the COVID-19 pandemic, with a projected net profit drop of over 90% for 2025 [1][2][4]. Group 1: Company Performance - YHLO Biotech's main business involves the development, production, and sales of in vitro diagnostic instruments and related reagents, focusing on various core disease areas [2][16]. - The company's revenue peaked in 2022, with a 238% increase, largely driven by the demand for COVID-19 antigen test kits [2][16]. - For 2023 and 2024, the company's revenue is projected to be 20.53 billion and 20.12 billion respectively, showing a year-on-year decline of 48.42% and 2.02% [4][18]. Group 2: Profit Forecast - YHLO Biotech announced on January 31 that it expects a net profit attributable to shareholders of 20 million to 30 million for 2025, a decrease of 270 million to 280 million from the previous year, representing a decline of 90.05% to 93.37% [4][19]. - The company's non-recurring net profit is expected to be between 65 million and 85 million, down 70.42% to 77.38% year-on-year [4][19]. Group 3: Strategic Partnership - On January 6, YHLO Biotech announced a strategic partnership with Shenzhen Brain-Computer Link Technology Co., Ltd. to develop brain-computer interface-related products [1][9]. - The partnership aims to integrate brain-computer interface technology with clinical and market resources to enhance diagnostic capabilities in central nervous system diseases [9][24]. - The company plans to invest no more than 15 million RMB in this partnership, which is still in its early stages and is not expected to significantly impact performance in the short term [12][26]. Group 4: Market Reaction and Regulatory Scrutiny - Following the announcement of the partnership, YHLO Biotech's stock price rose by 6.52%, with trading volume increasing by 299% [9][24]. - The Shanghai Stock Exchange issued an inquiry to YHLO Biotech regarding the clarity and accuracy of its disclosures related to the partnership, highlighting inconsistencies in the description of the technology involved [10][28]. - The company has been criticized for potentially engaging in "concept hype" by using vague language that could mislead investors about the nature of the technology [27][28].